Peptide Library

FDA-approved

Hormones & metabolism

Exenatide

Evidence

FDA approved

Class

GLP-1 receptor agonist

/

Exenatide

KEY TAKEAWAY

Exenatide is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster. It is sold as Byetta and Bydureon. The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GLP-1 receptor agonist

Approved for

Type 2 diabetes

Key fact

The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.

Route

Twice-daily or weekly subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Exenatide is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster. It is sold as Byetta and Bydureon.

How it works

How it works

It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and lowers appetite.

Regulatory status

Regulatory status

The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.

What it is used for

What it is used for

Type 2 diabetes.

Side effects and risks

Side effects and risks

Nausea is the most common effect. Pancreatitis is a rare serious risk, and the weekly form carries a boxed warning about thyroid C-cell tumors.

Citations

Citations

U.S. FDA prescribing information for Exenatide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo